Literature DB >> 24548046

A 'cure' for Down syndrome: what do parents want?

A Inglis1, Z Lohn, J C Austin, C Hippman.   

Abstract

Recent advancements in molecular genetics raise the possibility that therapeutics or a 'cure' for Down syndrome (DS) may become available. However, there are no data regarding how parents of children with DS perceive the possibility of mitigating specific manifestations such as the intellectual disability (ID) associated with DS, or curing the condition entirely. To explore these issues, we distributed a questionnaire to members of the Lower Mainland Down Syndrome Society in British Columbia, Canada. Questionnaires were completed by 101 parents (response rate=41%). A majority (61%) viewed the possibility of reversing ID in DS positively, but only 41% said that they would 'cure' their child of DS if it were possible. Twenty-seven percent of respondents said they would not 'cure' their child, and 32% were unsure if they would 'cure' their child. The most commonly cited motivation for opting for a 'cure' was to increase their child's independence. However, parental attitudes' towards a 'cure' for DS were complex, affected by ethical issues, perceived societal values, and pragmatic factors such as the age of the individual and long-term care-giving burden. These findings could be used by healthcare professionals supporting families who include a member with DS and to direct future research.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Down syndrome; attitudes; cure; intellectual disability; parents; therapeutics

Mesh:

Year:  2014        PMID: 24548046      PMCID: PMC4055389          DOI: 10.1111/cge.12364

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  34 in total

1.  Amniocentesis in sociocultural perspective.

Authors:  Rayna Rapp
Journal:  J Genet Couns       Date:  1993-09       Impact factor: 2.537

2.  Effects of donepezil on cognitive functioning in Down syndrome.

Authors:  N Johnson; C Fahey; B Chicoine; G Chong; D Gitelman
Journal:  Am J Ment Retard       Date:  2003-11

3.  Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

Authors:  James H Heller; Gail A Spiridigliozzi; P Murali Doraiswamy; Jennifer A Sullivan; Bythe G Crissman; Priya S Kishnani
Journal:  Am J Med Genet A       Date:  2004-10-15       Impact factor: 2.802

4.  Psychological well-being and coping in mothers of youths with autism, Down syndrome, or fragile X syndrome.

Authors:  Leonard Abbeduto; Marsha Mailick Seltzer; Paul Shattuck; Marty Wyngaarden Krauss; Gael Orsmond; Melissa M Murphy
Journal:  Am J Ment Retard       Date:  2004-05

5.  Syndrome specificity and behavioural disorders in young adults with intellectual disability: cultural differences in family impact.

Authors:  J Blacher; L L McIntyre
Journal:  J Intellect Disabil Res       Date:  2006-03

6.  Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.

Authors:  Ishita Das; Joo-Min Park; Jung H Shin; Soo Kyeong Jeon; Hernan Lorenzi; David J Linden; Paul F Worley; Roger H Reeves
Journal:  Sci Transl Med       Date:  2013-09-04       Impact factor: 17.956

7.  Stress trajectories in mothers of young children with Down syndrome.

Authors:  D E Most; D J Fidler; C Booth-LaForce; C Laforce-Booth; J Kelly
Journal:  J Intellect Disabil Res       Date:  2006-07

8.  Between 'desperation' and disability rights: a narrative analysis of complementary/alternative medicine use by parents for children with Down syndrome.

Authors:  Erica Prussing; Elisa J Sobo; Elizabeth Walker; Paul S Kurtin
Journal:  Soc Sci Med       Date:  2005-02       Impact factor: 4.634

9.  Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.

Authors:  James H Heller; Gail A Spiridigliozzi; Jennifer A Sullivan; P Murali Doraiswamy; Ranga R Krishnan; Priya S Kishnani
Journal:  Am J Med Genet A       Date:  2003-01-15       Impact factor: 2.802

10.  Emplotting children's lives: developmental delay vs. disability.

Authors:  Gail Landsman
Journal:  Soc Sci Med       Date:  2003-05       Impact factor: 4.634

View more
  4 in total

Review 1.  Is the search for cerebral palsy 'cures' a reasonable and appropriate goal in the 2020s?

Authors:  Ingrid Honan; Megan Finch-Edmondson; Christine Imms; Iona Novak; Amy Hogan; Shannon Clough; Bruce Bonyhady; Sarah McIntyre; Catherine Elliott; Shirley Wong; Michael Bink; Nadia Badawi
Journal:  Dev Med Child Neurol       Date:  2021-08-17       Impact factor: 4.864

2.  A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials.

Authors:  Saskia Hendriks; Christine Grady; David Wasserman; David Wendler; Diana W Bianchi; Benjamin E Berkman
Journal:  Am J Bioeth       Date:  2021-01-16       Impact factor: 11.229

Review 3.  From the lab to the people: major challenges in the biological treatment of Down syndrome.

Authors:  Jean A Rondal
Journal:  AIMS Neurosci       Date:  2021-02-09

4.  Views of patients and parents of children with genetic disorders on population-based expanded carrier screening.

Authors:  Anke J Woudstra; Lieke M van den Heuvel; Elsbeth H van Vliet-Lachotzki; Wybo Dondorp; Phillis Lakeman; Lotte Haverman; Irene M van Langen; Lidewij Henneman
Journal:  Prenat Diagn       Date:  2022-07-09       Impact factor: 3.242

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.